Verenigde Staten - Engels - NLM (National Library of Medicine)

remedyrepack inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 15 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii 1 as follows: generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: 1.      motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. 2.      autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. 3.      apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. 4.      vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling "on edge," irritability, impatience. the above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. however, mild depressive symptoms are common in gad. the effectiveness of buspirone hydrochloride tablets in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. there is no body of evidence available that systematically addresses the appropriate duration of treatment for gad. however, in a study of long-term use, 264 patients were treated with buspirone hydrochloride tablets for 1 year without ill effect. therefore, the physician who elects to use buspirone hydrochloride tablets for extended periods should periodically reassess the usefulness of the drug for the individual patient. buspirone hydrochloride tablets are contraindicated in patients hypersensitive to buspirone hydrochloride. the use of monoamine oxidase inhibitors (maois) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. the use of buspirone within 14 days of stopping an maoi intended to treat depression is also contraindicated. starting buspirone in a patient who is being treated with reversible maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome. (see warnings , dosage and administration  and drug interactions ) controlled substance class: buspirone hydrochloride is not a controlled substance. physical and psychological dependence: in human and animal studies, buspirone has shown no potential for abuse or diversion and there is no evidence that it causes tolerance, or either physical or psychological dependence. human volunteers with a history of recreational drug or alcohol usage were studied in two double-blind clinical investigations. none of the subjects were able to distinguish between buspirone hydrochloride tablets and placebo. by contrast, subjects showed a statistically significant preference for methaqualone and diazepam. studies in monkeys, mice, and rats have indicated that buspirone lacks potential for abuse. following chronic administration in the rat, abrupt withdrawal of buspirone did not result in the loss of body weight commonly observed with substances that cause physical dependency. although there is no direct evidence that buspirone hydrochloride tablets causes physical dependence or drug-seeking behavior, it is difficult to predict from experiments the extent to which a cns-active drug will be misused, diverted, and/or abused once marketed. consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of buspirone hydrochloride tablets misuse or abuse (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).

Verenigde Staten - Engels - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - sodium chloride (unii: 451w47iq8x) (sodium chloride - unii:451w47iq8x) - injection, solution - this parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.

Israël - Engels - Ministry of Health

eldan electronic instruments co ltd, israel - dextrose anhydrous; sodium chloride - solution for infusion - dextrose anhydrous 4.3 %w/v; sodium chloride 0.18 %w/v - sodium chloride - dextrose 4.3 % and 0.18 % sodium chloride vioser solution is used in the following indications: dehydration treatment due to a moderated loss of sodium and chloride (vomiting, diarrhoea, renal disorders, over use ofdiuretics) in cases where a source of energy is required (particularly starvation). paediatric population: this product should only be used in paediatric specialist settings (such as renal, hepatic and cardiac units, high dependency units and intensive care units) for intravenous fluid therapy requiring the use of 0.18% sodium chloride and4% glucose to maintain fluid and electrolyte balance.

Israël - Engels - Ministry of Health

teva medical ltd - sodium chloride - solution for injection - sodium chloride 0.9 g / 100 ml - sodium chloride - sodium chloride - a source of water and electrolytes. also indicated for use as priming solutions in hemodialysis procedures.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - sodium chloride 0.9%;  ;   - solution for injection - 0.9 % - active: sodium chloride 0.9%     excipient: hydrochloric acid sodium hydroxide water for injection - sodium chloride injection bp 0.9% can be used as the vehicle for the restoration of electrolytes, as the vehicle for parenteral drug administration or as a sterile irrigation medium.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium bicarbonate, quantity: 4.2 g - injection - excipient ingredients: disodium edetate; water for injections - sodium bicarbonate injection is indicated as an alkalinising agent in the treatment of metabolic acidosis which may occur in many conditions including diabetes, starvation, hepatitis, cardiac arrest, shock, severe dehydration, renal insufficiency, severe diarrhoea, addison's disease or administration of acidifying salts (e.g. excessive sodium chloride, calcium chloride, ammonium chloride). sodium bicarbonate injection is also used to increase urinary ph in order to increase the solubility of certain weak acids (e.g. cystine, sulphonamides, uric acid) and in the treatment of certain intoxications (e.g. methanol, phenobarbitone, salicylates, lithium) to decrease renal absorption of the drug or to correct acidosis.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 9 g - injection - excipient ingredients: water for injections - normal saline can be used as the vehicle for many parenteral drugs and as an electrolyte replenisher for maintenance or replacement of deficits of extracellular fluid. it can also be used as a sterile irrigation medium.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 4.5 g - injection - excipient ingredients: water for injections - normal saline can be used as the vehicle for many parenteral drugs and as an electrolyte replenisher for maintenance or replacement of deficits of extracellular fluid. it can also be used as a sterile irrigation medium.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 2.25 g - injection - excipient ingredients: water for injections - normal saline can be used as the vehicle for many parenteral drugs and as an electrolyte replenisher for maintenance or replacement of deficits of extracellular fluid. it can also be used as a sterile irrigation medium.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited t/a radpharm scientific - sodium oxidronate, quantity: 3.15 mg - injection, powder for - excipient ingredients: sodium chloride; stannous chloride dihydrate; dilute hydrochloric acid; gentisic acid; sodium hydroxide - technetium [99m tc] sodium oxidronate is a diagnostic skeletal imaging agent to demonstrate areas of altered osteogenesis in adult patients.